{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:10:02Z","timestamp":1759093802116,"version":"3.44.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019120","name":"Otsuka America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["U698"],"award-info":[{"award-number":["U698"]}],"id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005481","name":"School of Medicine, New York University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005481","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.ijcard.2014.03.003","type":"journal-article","created":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T20:46:03Z","timestamp":1394743563000},"page":"290-294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Bivalirudin in percutaneous coronary intervention: The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry"],"prefix":"10.1016","volume":"173","author":[{"given":"Martial","family":"Hamon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Nienaber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Lipiecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Amabile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efthymios","family":"Deliargyris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Lafont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2014.03.003_bb0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0149-2918(02)85004-4","article-title":"Bivalirudin: a direct thrombin inhibitor","volume":"24","author":"Gladwell","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijcard.2014.03.003_bb0010","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2014.03.003_bb0015","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.4244\/EIJV8I10A176","article-title":"Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial","volume":"8","author":"Tobbia","year":"2013","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ijcard.2014.03.003_bb0020","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4244\/EIJV9I1A17","article-title":"Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population","volume":"9","author":"Shelton","year":"2013","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ijcard.2014.03.003_bb0025","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.amjcard.2012.07.024","article-title":"Bleeding complications with regional adaptation of a prolonged bivalirudin regimen for ST-elevation acute myocardial infarction","volume":"110","author":"Mueller","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2014.03.003_bb0030","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ijcard.2011.09.059","article-title":"Prasugrel and bivalirudin for primary angioplasty: early results on stent thrombosis and bleeding","volume":"153","author":"Baumbach","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2014.03.003_bb0035","doi-asserted-by":"crossref","first-page":"905","DOI":"10.4244\/EIJV7I8A144","article-title":"HORIZONS-AMI Trial Investigators. Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial","volume":"7","author":"G\u00e9n\u00e9reux","year":"2011","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ijcard.2014.03.003_bb0040","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2014.03.003_bb0045","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(07)60450-4","volume":"369","author":"Stone","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2014.03.003_bb0050","doi-asserted-by":"crossref","first-page":"610","DOI":"10.4244\/EIJV3I5A109","article-title":"Ischaemic events and bleeding in patients undergoing percutaneous coronary intervention with concomitant bivalirudin treatment","volume":"3","author":"Madsen","year":"2008","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ijcard.2014.03.003_bb0055","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nrcardio.2012.61","article-title":"Direct thrombin inhibitors in cardiovascular disease","volume":"9","author":"Arsenault","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ijcard.2014.03.003_bb0060","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","volume":"377","author":"Stone","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2014.03.003_bb0065","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.jacc.2011.01.038","article-title":"Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the Horizons-switch analysis","volume":"57","author":"Dangas","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2014.03.003_bb0070","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.amjcard.2011.06.033","article-title":"Effect of prolonged bivalirudin infusion on ST-segment resolution following primary percutaneous coronary intervention (from the PROBI VIRI 2 study)","volume":"108","author":"Cortese","year":"2011","journal-title":"Am J Cardiol"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314004276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527314004276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:35:04Z","timestamp":1759091704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527314004276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0167527314004276"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.03.003","relation":{},"ISSN":["0167-5273"],"issn-type":[{"type":"print","value":"0167-5273"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bivalirudin in percutaneous coronary intervention: The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2014.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}